| Literature DB >> 9053736 |
M J Vaz-da-Silva1, S Guimarães, D Moura.
Abstract
This study aimed at characterizing the influence of endothelium on noradrenaline release from the canine pulmonary artery. Tritium overflow from intact or endothelium-free vessels preloaded with 0.2 mumol.l-1 3H-noradrenaline was evoked by electrical stimulation (1 Hz, during 5 min) or potassium (25-100 mmol.l-1). The fractional release of tritium evoked by electrical stimulation was increased by removing the endothelium [from 1.7 (1.2; 2.4) to 2.7(2.3; 3.2) x 10(-5).pulse-1, n = 10; P < 0.05]. Neither NG-nitro-L-arginine methyl ester (L-NAME) (up to 300 mumol.l-1) nor indomethacin (up to 30 mumol.l-1), nor endothelin-1 (up to 30 nmol.l-1), nor suramin (up to 300 mumol.l-1) changed tritium release evoked by electrical stimulation. In contrast, the selective A1-adenosine antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (3.3-33 nmol.l-1) concentration-dependently increased, and the selective A1-adenosine agonist N6-cyclopentyladenosine (CPA) (3.3-100 nmol.l-1) concentration-dependently decreased the evoked release of noradrenaline. Since the effects of DPCPX were observed in endothelium-intact tissues only, it may be concluded that adenosine secreted by the endothelium activates prejunctional release-inhibiting A1-receptors. Tetraethylammonium (TEA) (3.3-33 mmol.l-1) enhanced tritium overflow evoked by electrical stimulation more in endothelium-free than in endothelium-intact vessels, indicating that some K(+)-channel opener is involved in the inhibitory role of endothelium on noradrenaline release. Since it had been previously shown that A1-adenosine receptors are coupled to K(+)-channels, it is suggested that adenosine may inhibit noradrenaline release through the opening of K(+)-channels. In conclusion, the results show that in the canine pulmonary artery, adenosine is a good candidate for the endothelium-dependent inhibitory factor which is responsible for the reduction of noradrenaline release evoked by electrical stimulation.Entities:
Mesh:
Substances:
Year: 1995 PMID: 9053736 DOI: 10.1007/bf00171323
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000